{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jabbour SK"],"funding":["NCI NIH HHS","NIH"],"pagination":["665-679"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8600025"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["113(6)"],"pubmed_abstract":["Although the development of effective combined chemoradiation regimens for esophageal cancers has resulted in statistically significant survival benefits, the majority of patients treated with curative intent develop locoregional and/or distant relapse. Further improvements in disease control and survival will require the development of individualized therapy based on the knowledge of host and tumor genomics and potentially harnessing the host immune system. Although there are a number of gene targets that are amplified and proteins that are overexpressed in esophageal cancers, attempts to target several of these have not proven successful in unselected patients. Herein, we review our current state of knowledge regarding the molecular pathways implicated in esophageal carcinoma, and the av"],"journal":["Journal of the National Cancer Institute"],"pubmed_title":["Potential Molecular Targets in the Setting of Chemoradiation for Esophageal Malignancies."],"pmcid":["PMC8600025"],"funding_grant_id":["P30 CA008748"],"pubmed_authors":["Ajani JA","Haddock M","Lin S","Wong R","Sayan M","Ilson D","Ahmed MM","Rustgi AK","Jabbour SK","Prasanna PG","Coleman N","Jamorabo D","Williams TM","Miller ED","Vikram B","Chang AC","Kunos C","El-Rifai W","Liu G"],"additional_accession":[]},"is_claimable":false,"name":"Potential Molecular Targets in the Setting of Chemoradiation for Esophageal Malignancies.","description":"Although the development of effective combined chemoradiation regimens for esophageal cancers has resulted in statistically significant survival benefits, the majority of patients treated with curative intent develop locoregional and/or distant relapse. Further improvements in disease control and survival will require the development of individualized therapy based on the knowledge of host and tumor genomics and potentially harnessing the host immune system. Although there are a number of gene targets that are amplified and proteins that are overexpressed in esophageal cancers, attempts to target several of these have not proven successful in unselected patients. Herein, we review our current state of knowledge regarding the molecular pathways implicated in esophageal carcinoma, and the av","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jun","modification":"2025-04-22T08:13:23.271Z","creation":"2022-02-11T13:00:56.537Z"},"accession":"S-EPMC8600025","cross_references":{"pubmed":["33351071"],"doi":["10.1093/jnci/djaa195"]}}